S&P Futures
3,944.75 +47.00 (+1.21%) Dow Futures
31,504.00 +302.00 (+0.97%) Nasdaq Futures
12,079.25 +201.00 (+1.69%) Russell 2000 Futures
1,800.80 +25.90 (+1.46%) Crude Oil
111.65 -0.56 (-0.50%) Gold
1,842.20 +1.00 (+0.05%)
RedHill Biopharma Ltd. (RDHL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0700 |
| Open | 1.0500 |
| Bid | 0.9600 x 1000 |
| Ask | 2.1800 x 1300 |
| Day's Range | 1.0200 - 1.1300 |
| 52 Week Range | 0.9000 - 11.1800 |
| Volume | |
| Avg. Volume | 419,004 |
| Market Cap | 55.022M |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2410 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.38 |
- American City Business Journals
Raleigh drugmaker pursuing Covid treatment raising $15M to fund acquisitions
Additionally, the company agreed to issue unregistered private warrants to the investor to purchase up to more than 13 million shares at $1.48 a share in a concurrent private placement, according to a filing with the U.S. Securities and Exchange Commission. RedHill's stock fell more than 30 percent Monday after the company disclosed the offering prior to markets opening. The offering follows the company signing a licensing deal with the South Korean corporation Kubo Co. Ltd for the exclusive rights to commercialize RedHill's investigational Covid-19 treatment called opaganib.
- PR Newswire
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a definitive agreement with a single leading healthcare investor for the purchase and sale of 10,563,380 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents), each ADS representing ten (10) ordinary shares, at a purchase price of $1.42 per ADS (or ADS equivalent), in a registered direct offering. RedHill has also agreed to issue
- Insider Monkey
Cathie Wood’s Latest Portfolio: 10 New Stock Picks in 2022
In this article we will discuss some new stock picks of Cathie Wood’s hedge fund. You can skip this part and go directly to see the top 5 New Stock Picks of Cathie Wood in 2022. Despite huge criticism and losses, Cathie Wood’s hedge fund ARK Investment continues to attract investors amid promises of future […]
